A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

NCT02353598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Crenezumab dose level 1
DRUG: Crenezumab dose level 2
DRUG: Crenezumb dose level 3
DRUG: Placebo

Sponsor

Genentech, Inc.